Tessera Therapeutics

company

About

Tessera Therapeutics is a biotechnology company that focuses on a new category of genetic medicines.

Details

Last Funding Type
Series C
Last Funding Money Raised
$300M
Industries
Biopharma,Biotechnology,Genetics,Life Science,Therapeutics
Founded date
Jan 1, 2018
Number Of Employee
101 - 250
Operating Status
Active
Legal Name
Tessera Therapeutics, Inc.

Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source. Gene Writing holds the potential to become a new category in genetic medicine, building upon recent breakthroughs in gene therapy and gene editing while eliminating important limitations in their reach, utilization, and efficacy. Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
$530M $2.70M
Tessera Therapeutics has raised a total of $530M $2.70M in funding over 2 rounds. Their latest funding was raised on Apr 19, 2022 from a Series C round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Apr 19, 2022 Series C $300M 12 Detail
Jan 12, 2021 Series B $230M 6 Alaska Permanent Fund
SoftBank Vision Fund
Detail
May 7, 2020 Seed $2.70M Detail

Employee Profiles

Number of Employee Profiles
4
Tessera Therapeutics has 4 current employee profiles, including Executive Geoffrey von Maltzahn
Executive
Executive
Executive